Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of FLX475 in Combination With Ipilimumab in Advanced Melanoma

NCT04894994 is registered in ClinicalTrials.gov with RAPT Therapeutics, Inc. as lead sponsor.

NCT NCT04894994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04894994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of FLX475 in Combination With Ipilimumab in Advanced Melanoma
Lead sponsor
RAPT Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
September 3, 2021
Completion date
September 13, 2022
Enrollment
6 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma